Evidence
Continuous menopause care needs evidence that follows the patient over time.

Menopathway is designed to collect clinically useful context from Vela, diagnostics, clinician review, and care-plan changes so menopause support can be measured as a pathway, not as isolated appointments.

NICE NG23 informed BMS-aligned protocols Clinician-led review Real-world outcomes
Patient evidence

What is changing between reviews

Vela captures symptom severity, triggers, sleep, mood, cognition, bleeding patterns, medication response, and patient-reported goals over time.

  • Weekly check-ins and baseline assessment
  • Longitudinal symptom timeline
  • Patient context available for clinician review
Clinical evidence

What clinicians need to act safely

Menopathway Clinician connects patient history with diagnostics, care-plan decisions, safety checks, and structured follow-up notes.

  • Clinician-reviewed patterns and red-flag prompts
  • Diagnostics and biomarker context where relevant
  • Care-plan changes recorded against symptoms and goals
Evidence loop
Track, test, review, adjust, measure.

The Menopathway model is built around repeated clinical context: what was reported, what was tested, what changed, and whether the patient improved.

1
Track
Vela records symptoms, goals, and treatment response across time.
2
Test
Diagnostics are used when they can support safer decisions.
3
Review
Clinicians review the timeline, risks, and patient priorities.
4
Adjust
Care plans change with symptoms, safety context, and outcomes.
Commissioning view

What the pathway can report

  • Engagement and follow-up completion
  • Symptom trajectory and patient-reported outcome trends
  • Diagnostics utilisation and result handling
  • Medication and care-plan change history
  • Escalation, safety, and audit events
Clinical caution

Planning evidence, not a submitted NICE appraisal

QALY, ICER, and cost-offset language should be used carefully, sourced clearly, and separated from consumer claims. Formal economic submissions require full governance, data review, and appropriate external scrutiny.